NO324554B1 - Anvendelse av et kjemisk modifisert polypeptid for fremstilling av et farmasoytisk preparat for a fremme blodplateproduksjon, samt kjemisk modifisert polypeptid. - Google Patents

Anvendelse av et kjemisk modifisert polypeptid for fremstilling av et farmasoytisk preparat for a fremme blodplateproduksjon, samt kjemisk modifisert polypeptid. Download PDF

Info

Publication number: NO324554B1
Authority: NO; Norway
Prior art keywords: chemically modified; formula; amino acid; group; replaced
Prior art date: 1994-02-23

Application number

NO19963493A

Other languages

English (en)

Norwegian (no)

Other versions

NO963493D0 (no

NO963493L (no

Inventor

Motoo Yamasaki

Masami Okabe

Toshiyuki Suzawa

Ken Kobayashi

Kumiko Maruyama

Original Assignee

Kyowa Hakko Kogyo Kk

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-02-23

Filing date

1996-08-22

Publication date

2007-11-19

1996-08-22 Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk

1996-08-22 Publication of NO963493D0 publication Critical patent/NO963493D0/no

1996-10-23 Publication of NO963493L publication Critical patent/NO963493L/no

2007-11-19 Publication of NO324554B1 publication Critical patent/NO324554B1/no

Links

102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 44
108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 44
229920001184 polypeptide Polymers 0.000 title claims abstract description 41
238000004519 manufacturing process Methods 0.000 title claims abstract description 8
238000002360 preparation method Methods 0.000 title claims description 21
230000001737 promoting effect Effects 0.000 title claims description 16
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
239000000126 substance Substances 0.000 claims abstract description 32
-1 amino, carboxyl Chemical group 0.000 claims abstract description 19
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims abstract description 11
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims abstract description 9
150000001413 amino acids Chemical group 0.000 claims description 44
239000002202 Polyethylene glycol Substances 0.000 claims description 34
229920001223 polyethylene glycol Polymers 0.000 claims description 34
235000001014 amino acid Nutrition 0.000 claims description 29
150000002334 glycols Chemical class 0.000 claims description 28
229920001515 polyalkylene glycol Polymers 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 12
229910052717 sulfur Inorganic materials 0.000 claims description 12
229910052736 halogen Inorganic materials 0.000 claims description 11
150000002367 halogens Chemical class 0.000 claims description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 10
239000004473 Threonine Substances 0.000 claims description 10
229920001577 copolymer Polymers 0.000 claims description 9
229920001451 polypropylene glycol Polymers 0.000 claims description 9
125000002252 acyl group Chemical group 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
239000004475 Arginine Substances 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 5
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
235000004279 alanine Nutrition 0.000 claims description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
235000018417 cysteine Nutrition 0.000 claims description 5
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
239000004698 Polyethylene Substances 0.000 claims description 4
229920000573 polyethylene Polymers 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
238000000034 method Methods 0.000 abstract description 14
239000000203 mixture Substances 0.000 abstract description 14
230000000694 effects Effects 0.000 abstract description 13
239000003795 chemical substances by application Substances 0.000 abstract description 12
230000003247 decreasing effect Effects 0.000 abstract description 12
239000002552 dosage form Substances 0.000 abstract description 4
101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 abstract description 2
239000000243 solution Substances 0.000 description 65
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 47
229910052921 ammonium sulfate Inorganic materials 0.000 description 47
235000011130 ammonium sulphate Nutrition 0.000 description 47
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
239000000872 buffer Substances 0.000 description 37
238000006243 chemical reaction Methods 0.000 description 36
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 33
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
239000002244 precipitate Substances 0.000 description 17
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
238000005406 washing Methods 0.000 description 16
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 15
241000699670 Mus sp. Species 0.000 description 13
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
238000010828 elution Methods 0.000 description 12
239000008363 phosphate buffer Substances 0.000 description 12
150000001735 carboxylic acids Chemical class 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
239000012506 Sephacryl® Substances 0.000 description 10
210000004027 cell Anatomy 0.000 description 10
150000001875 compounds Chemical class 0.000 description 10
239000002904 solvent Substances 0.000 description 10
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
229910052786 argon Inorganic materials 0.000 description 8
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 7
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 7
238000003756 stirring Methods 0.000 description 7
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000001914 filtration Methods 0.000 description 6
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 6
238000011084 recovery Methods 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
239000002198 insoluble material Substances 0.000 description 5
239000002808 molecular sieve Substances 0.000 description 5
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 5
239000007787 solid Substances 0.000 description 5
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
238000011725 BALB/c mouse Methods 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
241001529936 Murinae Species 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
210000002798 bone marrow cell Anatomy 0.000 description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
238000007385 chemical modification Methods 0.000 description 3
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000005194 fractionation Methods 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
239000008103 glucose Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
108091005601 modified peptides Proteins 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
239000011148 porous material Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
210000003462 vein Anatomy 0.000 description 3
NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 2
ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102000004889 Interleukin-6 Human genes 0.000 description 2
108090001005 Interleukin-6 Proteins 0.000 description 2
102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241001415846 Procellariidae Species 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
102000036693 Thrombopoietin Human genes 0.000 description 2
108010041111 Thrombopoietin Proteins 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
GLESHRYLRAOJPS-DHCFDGJBSA-N conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
229940100601 interleukin-6 Drugs 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000010998 test method Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
QRAFJHXNLQTXQW-UHFFFAOYSA-N 2-methylpropyl hydrogen carbonate Chemical compound CC(C)COC(O)=O QRAFJHXNLQTXQW-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
102000000646 Interleukin-3 Human genes 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000003995 blood forming stem cell Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003677 hemocyte Anatomy 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940076264 interleukin-3 Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920005606 polypropylene copolymer Polymers 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000011160 research Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000002689 soil Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
239000012137 tryptone Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO19963493A 1994-02-23 1996-08-22 Anvendelse av et kjemisk modifisert polypeptid for fremstilling av et farmasoytisk preparat for a fremme blodplateproduksjon, samt kjemisk modifisert polypeptid. NO324554B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2573594		1994-02-23
PCT/JP1995/000266 WO1995023165A1 (en)	1994-02-23	1995-02-23	Platelet growth accelerator

Publications (3)

Publication Number	Publication Date
NO963493D0 NO963493D0 (no)	1996-08-22
NO963493L NO963493L (no)	1996-10-23
NO324554B1 true NO324554B1 (no)	2007-11-19

Family

ID=12174082

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19963493A NO324554B1 (no)	1994-02-23	1996-08-22	Anvendelse av et kjemisk modifisert polypeptid for fremstilling av et farmasoytisk preparat for a fremme blodplateproduksjon, samt kjemisk modifisert polypeptid.

Country Status (17)

Country	Link
US (2)	US6245900B1 (de)
EP (1)	EP0744409B9 (de)
JP (1)	JP4011106B2 (de)
KR (1)	KR100403688B1 (de)
CN (1)	CN1097058C (de)
AT (1)	ATE403677T1 (de)
AU (1)	AU711535B2 (de)
CA (1)	CA2183871C (de)
DE (1)	DE69535801D1 (de)
DK (1)	DK0744409T3 (de)
ES (1)	ES2312166T3 (de)
FI (1)	FI120647B (de)
HU (1)	HU217872B (de)
NO (1)	NO324554B1 (de)
NZ (1)	NZ281329A (de)
PT (1)	PT744409E (de)
WO (1)	WO1995023165A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4011124B2 (ja)	1997-06-06	2007-11-21	協和醗酵工業株式会社	化学修飾ポリペプチド
DE69834500T2 (de)	1997-09-05	2007-05-03	Kyowa Hakko Kogyo Co., Ltd.	Xanthinderivative zur behandlung von hirnischämie
US6555660B2 (en)	2000-01-10	2003-04-29	Maxygen Holdings Ltd.	G-CSF conjugates
US6831158B2 (en)	2000-01-10	2004-12-14	Maxygen Holdings Ltd.	G-CSF conjugates
US6646110B2 (en)	2000-01-10	2003-11-11	Maxygen Holdings Ltd.	G-CSF polypeptides and conjugates
EP1425304B9 (de)	2001-07-11	2010-09-08	Maxygen, Inc.	G-csf konjugate
CA2467557A1 (en) *	2001-11-19	2003-05-30	Kyowa Hakko Kogyo Co., Ltd.	Agent which mobilizes multipotential stem cells from tissues to peripheral blood
US7992725B2 (en)	2002-05-03	2011-08-09	Biomet Biologics, Llc	Buoy suspension fractionation system
US7374678B2 (en)	2002-05-24	2008-05-20	Biomet Biologics, Inc.	Apparatus and method for separating and concentrating fluids containing multiple components
US6905612B2 (en) *	2003-03-21	2005-06-14	Hanuman Llc	Plasma concentrate apparatus and method
US7832566B2 (en)	2002-05-24	2010-11-16	Biomet Biologics, Llc	Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US20040182795A1 (en) *	2003-03-21	2004-09-23	Randel Dorian	Apparatus and method for concentration of plasma from whole blood
US20030205538A1 (en) *	2002-05-03	2003-11-06	Randel Dorian	Methods and apparatus for isolating platelets from blood
US20060278588A1 (en)	2002-05-24	2006-12-14	Woodell-May Jennifer E	Apparatus and method for separating and concentrating fluids containing multiple components
US7845499B2 (en)	2002-05-24	2010-12-07	Biomet Biologics, Llc	Apparatus and method for separating and concentrating fluids containing multiple components
WO2003099412A1 (en)	2002-05-24	2003-12-04	Biomet Manufacturing Corp.	Apparatus and method for separating and concentrating fluids containing multiple components
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
ES2532479T3 (es) *	2004-01-28	2015-03-27	Kyowa Hakko Kirin Co., Ltd.	Agentes para el tratamiento de la migraña
US7866485B2 (en)	2005-02-07	2011-01-11	Hanuman, Llc	Apparatus and method for preparing platelet rich plasma and concentrates thereof
US7708152B2 (en)	2005-02-07	2010-05-04	Hanuman Llc	Method and apparatus for preparing platelet rich plasma and concentrates thereof
ES2426172T3 (es) *	2005-02-07	2013-10-21	Hanuman Llc	Dispositivo concentrador de plasma
ES2426941T3 (es)	2005-02-07	2013-10-25	Hanuman Llc	Aparato y procedimiento de concentrados de plasma rico en plaquetas
US7694828B2 (en)	2005-04-27	2010-04-13	Biomet Manufacturing Corp.	Method and apparatus for producing autologous clotting components
KR20080027291A (ko)	2005-06-01	2008-03-26	맥시겐 홀딩스 엘티디	피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
US8567609B2 (en)	2006-05-25	2013-10-29	Biomet Biologics, Llc	Apparatus and method for separating and concentrating fluids containing multiple components
JP5479319B2 (ja)	2007-04-12	2014-04-23	バイオメット・バイオロジックス・リミテッド・ライアビリティ・カンパニー	ブイ式懸濁液分画システム
US8328024B2 (en)	2007-04-12	2012-12-11	Hanuman, Llc	Buoy suspension fractionation system
MX2010002448A (es)	2007-08-27	2010-10-04	Biogenerix Ag	Formulacion liquida del g-csf conjugado.
EP2567692B1 (de)	2008-02-27	2016-04-06	Biomet Biologics, LLC	Verwendung einer Vorrichtung zur Erzeugung Interleukin-1-rezeptorantagonistreicher Lösungen
WO2009111338A1 (en)	2008-02-29	2009-09-11	Biomet Manufacturing Corp.	A system and process for separating a material
US8012077B2 (en)	2008-05-23	2011-09-06	Biomet Biologics, Llc	Blood separating device
US8187475B2 (en)	2009-03-06	2012-05-29	Biomet Biologics, Llc	Method and apparatus for producing autologous thrombin
US8313954B2 (en)	2009-04-03	2012-11-20	Biomet Biologics, Llc	All-in-one means of separating blood components
US9011800B2 (en)	2009-07-16	2015-04-21	Biomet Biologics, Llc	Method and apparatus for separating biological materials
US8591391B2 (en)	2010-04-12	2013-11-26	Biomet Biologics, Llc	Method and apparatus for separating a material
US9642956B2 (en)	2012-08-27	2017-05-09	Biomet Biologics, Llc	Apparatus and method for separating and concentrating fluids containing multiple components
US10208095B2 (en)	2013-03-15	2019-02-19	Biomet Manufacturing, Llc	Methods for making cytokine compositions from tissues using non-centrifugal methods
US10143725B2 (en)	2013-03-15	2018-12-04	Biomet Biologics, Llc	Treatment of pain using protein solutions
US20140271589A1 (en)	2013-03-15	2014-09-18	Biomet Biologics, Llc	Treatment of collagen defects using protein solutions
US9895418B2 (en)	2013-03-15	2018-02-20	Biomet Biologics, Llc	Treatment of peripheral vascular disease using protein solutions
US9950035B2 (en)	2013-03-15	2018-04-24	Biomet Biologics, Llc	Methods and non-immunogenic compositions for treating inflammatory disorders
US9550028B2 (en)	2014-05-06	2017-01-24	Biomet Biologics, LLC.	Single step desiccating bead-in-syringe concentrating device
US9713810B2 (en)	2015-03-30	2017-07-25	Biomet Biologics, Llc	Cell washing plunger using centrifugal force
US9757721B2 (en)	2015-05-11	2017-09-12	Biomet Biologics, Llc	Cell washing plunger using centrifugal force
US10485627B2 (en) *	2016-04-07	2019-11-26	Ethicon, Inc.	Containment sleeves for packages containing medical devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5959629A (ja) *	1982-09-27	1984-04-05	Nippon Chem Res Kk	効力持続性組成物
DE3380726D1 (en)	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
US4968616A (en) *	1986-05-16	1990-11-06	Masayasu Inoue	Superoxide dismutase derivatives, method of producing same and medicinal use of same
JPS6360938A (ja) *	1986-09-02	1988-03-17	Meiji Milk Prod Co Ltd	修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
US5681720A (en)	1986-12-23	1997-10-28	Kyowa Hakko Co., Ltd.	DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
NO176799C (no)	1986-12-23	1995-05-31	Kyowa Hakko Kogyo Kk	DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US5214132A (en) *	1986-12-23	1993-05-25	Kyowa Hakko Kogyo Co., Ltd.	Polypeptide derivatives of human granulocyte colony stimulating factor
JP2532515B2 (ja)	1987-10-08	1996-09-11	水澤化学工業株式会社	血液凝集凝固剤
JPH0796558B2 (ja) *	1988-03-31	1995-10-18	協和醗酵工業株式会社	修飾ポリペプチド
CA1340810C (en) *	1988-03-31	1999-11-02	Motoo Yamasaki	Polypeptide derivatives of human granulocyte colony stimulating factor
WO1990006952A1 (fr)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5342940A (en)	1989-05-27	1994-08-30	Sumitomo Pharmaceuticals Company, Limited	Polyethylene glycol derivatives, process for preparing the same
IL96477A0 (en) *	1989-12-01	1991-08-16	Amgen Inc	Megakaryocyte production
JPH03215499A (ja) *	1990-01-19	1991-09-20	Green Cross Corp:The	ヘモグロビン複合体
JP2975632B2 (ja) *	1990-03-30	1999-11-10	生化学工業株式会社	グリコサミノグリカン修飾プロテイン
IE912365A1 (en)	1990-07-23	1992-01-29	Zeneca Ltd	Continuous release pharmaceutical compositions
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor

1995
- 1995-02-23 JP JP52225695A patent/JP4011106B2/ja not_active Expired - Fee Related
- 1995-02-23 ES ES95909967T patent/ES2312166T3/es not_active Expired - Lifetime
- 1995-02-23 CA CA002183871A patent/CA2183871C/en not_active Expired - Lifetime
- 1995-02-23 PT PT95909967T patent/PT744409E/pt unknown
- 1995-02-23 WO PCT/JP1995/000266 patent/WO1995023165A1/ja not_active Ceased
- 1995-02-23 HU HU9602312A patent/HU217872B/hu not_active IP Right Cessation
- 1995-02-23 KR KR1019960704628A patent/KR100403688B1/ko not_active Expired - Fee Related
- 1995-02-23 EP EP95909967A patent/EP0744409B9/de not_active Expired - Lifetime
- 1995-02-23 AT AT95909967T patent/ATE403677T1/de active
- 1995-02-23 CN CN95192717A patent/CN1097058C/zh not_active Expired - Fee Related
- 1995-02-23 NZ NZ281329A patent/NZ281329A/en not_active IP Right Cessation
- 1995-02-23 US US08/696,988 patent/US6245900B1/en not_active Expired - Lifetime
- 1995-02-23 DK DK95909967T patent/DK0744409T3/da active
- 1995-02-23 AU AU18237/95A patent/AU711535B2/en not_active Ceased
- 1995-02-23 DE DE69535801T patent/DE69535801D1/de not_active Expired - Lifetime
1996
- 1996-08-22 NO NO19963493A patent/NO324554B1/no not_active IP Right Cessation
- 1996-08-22 FI FI963278A patent/FI120647B/fi not_active IP Right Cessation
2005
- 2005-10-20 US US11/253,617 patent/US7592311B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0744409A4 (de)	1998-09-09
KR100403688B1 (ko)	2004-02-05
DK0744409T3 (da)	2008-11-10
HU217872B (hu)	2000-04-28
WO1995023165A1 (en)	1995-08-31
EP0744409A1 (de)	1996-11-27
HK1017818A1 (en)	1999-11-26
CA2183871A1 (en)	1995-08-31
EP0744409B1 (de)	2008-08-06
JP4011106B2 (ja)	2007-11-21
ES2312166T3 (es)	2009-02-16
FI963278A0 (fi)	1996-08-22
CA2183871C (en)	2008-11-04
NO963493D0 (no)	1996-08-22
PT744409E (pt)	2008-11-03
EP0744409B9 (de)	2009-08-19
US7592311B2 (en)	2009-09-22
US6245900B1 (en)	2001-06-12
CN1097058C (zh)	2002-12-25
AU711535B2 (en)	1999-10-14
HU9602312D0 (en)	1996-10-28
ATE403677T1 (de)	2008-08-15
DE69535801D1 (de)	2008-09-18
NZ281329A (en)	1997-07-27
AU1823795A (en)	1995-09-11
FI120647B (fi)	2010-01-15
FI963278L (fi)	1996-08-22
HUT74807A (en)	1997-02-28
US20060040865A1 (en)	2006-02-23
NO963493L (no)	1996-10-23
CN1150434A (zh)	1997-05-21

Legal Events

Date	Code	Title	Description
2014-09-22	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO324554B1 (no)	2007-11-19	Anvendelse av et kjemisk modifisert polypeptid for fremstilling av et farmasoytisk preparat for a fremme blodplateproduksjon, samt kjemisk modifisert polypeptid.
JP4011124B2 (ja)	2007-11-21	化学修飾ポリペプチド
JPWO1995023165A1 (ja)	1996-07-30	血小板増殖促進剤
EP0335423B1 (de)	1995-08-09	Modifizierter humaner G-CSF
JP2989002B2 (ja)	1999-12-13	化学修飾顆粒球コロニー刺激因子
US6166183A (en)	2000-12-26	Chemically-modified G-CSF
JPWO1998055500A1 (ja)	1999-11-24	化学修飾ポリペプチド
JPWO1990006952A1 (ja)	1990-11-01	化学修飾顆粒球コロニー刺激因子
EP0217404B1 (de)	1992-01-15	Einen menschlichen Granulozytkoloniereizfaktor für die Behandlung von Leukopenien enthaltende pharmazeutische Zubereitung
JP3966885B2 (ja)	2007-08-29	血小板増殖促進剤
CN101356190B (zh)	2012-11-14	用于抑制pf4和rantes相互作用的拮抗剂
HK1017818B (en)	2009-06-05	Platelet growth accelerator
CA2311684C (en)	2002-12-10	Chemically-modified g-csf
HU218489B (hu)	2000-09-28	Vérlemezke termelődést elősegítő polipeptidek